Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
The Motley Fool on MSN1d
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
The company's latest presentation supports the idea that its lead program will make billions.
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
Viking Therapeutics stock falling amid results for new GLP-1 pill
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...
The Motley Fool on MSN3d
Is Viking Therepautics a Buy Now?
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
MM&M3d
Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Promising Growth Potential for Keros Therapeutics Driven by Robust Clinical Pipeline and Upcoming Data Releases
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing ...